Last reviewed · How we verify
JS006 as Monotherapy
At a glance
| Generic name | JS006 as Monotherapy |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors (PHASE1)
- A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies (PHASE1)
- A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies (PHASE1)
- The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JS006 as Monotherapy CI brief — competitive landscape report
- JS006 as Monotherapy updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI